Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R, et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...
Kumar V, Murali S, Goldberg J, Alonso B, Moretó-Planas L, et al.
2024-01-02 • JAC-Antimicrobial Resistance
2024-01-02 • JAC-Antimicrobial Resistance
OBJECTIVES To describe the prevalence of common bacterial pathogens and antibiotic susceptibility patterns amongst advanced HIV disease (AHD) patients admitted between May 2019 and M...
Chandna A, Mahajan R, Gautam P, Mwandigha L, Dittrich S, et al.
2023-08-21 • PLOS Global Public Health
2023-08-21 • PLOS Global Public Health
The soluble urokinase plasminogen activator receptor (suPAR) has been proposed as a biomarker for risk stratification of patients presenting with acute infections. However, most studies ...
Chandna A, PRIORITISE Study Group, Mahajan R, Gautam P, Mwandigha L, et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
INTRODUCTION In locations where few people have received Covid-19 vaccines, health systems remain vulnerable to spikes in SARS-CoV-2 infections. Triage tools, which could include bio...
Mahajan R, Owen SI, Kazmi S, Das P, Pandey K, et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION People co-infected with visceral leishmaniasis and HIV (VL-HIV) typically present with advanced HIV disease and in poor clinical condition. The reasons for this are comp...
Raguenaud ME, Isaakidis P, Zachariah R, Te V, Soeung S, et al.
2009-08-20 • BMC Pediatrics
2009-08-20 • BMC Pediatrics
BACKGROUND Although HIV program evaluations focusing on mortality on ART provide important evidence on treatment effectiveness, they do not asses overall HIV program performance beca...
People living with HIV (PLHIV) have an increased risk of developing visceral leishmaniasis (VL) and poor outcomes compared to HIV negative individuals. Here, we aim to establish the prev...
Chandna A, Mahajan R, Gautam P, Mwandigha L, Gunasekaran K, et al.
2022-03-21 • Clinical Infectious Diseases
2022-03-21 • Clinical Infectious Diseases
BACKGROUND In locations where few people have received COVID-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. Tools to identify patients suitable for...
Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D, et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND Visceral leishmaniasis (VL) in patients living with Human-Immunodeficiency-Virus (HIV) present an increasingly important patient cohort in areas where both infections are ...
Isaakidis P, Raguenaud ME, Te V, Tray CS, Akao K, et al.
2010-03-21 • Journal of the International AIDS Society
2010-03-21 • Journal of the International AIDS Society
ABSTRACT: BACKGROUND: Long-term outcomes of antiretroviral therapy (ART) in children remain poorly documented in resource-limited settings. The objective of this study was to assess two-...
